Sevoflurane and QTc prolongation: An interesting observation, or a clinically significant finding?

Anesthesiology

Volumn 113, Issue 4, 2010, Pages 772-775

  Scuderi, Phillip E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DIGITALIS; DOFETILIDE; IBUTILIDE; POTASSIUM CHANNEL HERG; SEVOFLURANE; ETHER DERIVATIVE; INHALATION ANESTHETIC AGENT; POTASSIUM CHANNEL BLOCKING AGENT; SHAKER POTASSIUM CHANNEL;

BRADYCARDIA; CONGESTIVE HEART FAILURE; DISEASE PREDISPOSITION; DOSE RESPONSE; EDITORIAL; GENE MUTATION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DEPOLARIZATION; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOKALEMIA; PERIOPERATIVE PERIOD; POTASSIUM CURRENT; PRIORITY JOURNAL; QT PROLONGATION; RISK FACTOR; SEX DIFFERENCE; SUDDEN DEATH; TORSADE DES POINTES; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; LONG QT SYNDROME; NOTE; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTMARKETING SURVEILLANCE; RISK ASSESSMENT;

ANESTHETICS, INHALATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LONG QT SYNDROME; METHYL ETHERS; POTASSIUM CHANNEL BLOCKERS; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT; SHAKER SUPERFAMILY OF POTASSIUM CHANNELS; TORSADES DE POINTES;

EID: 77957899580     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181f2b088     Document Type: Editorial

References (33)

1. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH: Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287:2215-2220
2. Han DW, Park K, Jang SB, Kern SE: Modeling the effect of sevoflurane on corrected QT prolongation: A pharmacodynamic analysis. ANESTHESIOLOGY 2010; 113:806-811
3. Michaloudis D, Fraidakis O, Petrou A, Gigourtsi C, Parthenakis F: Anaesthesia and the QT interval. Effects of isoflurane and halothane in unpremedicated children. Anaesthesia 1998; 53:435-439 (Pubitemid 28223072)
4. Yildirim H, Adanir T, Atay A, Katircioǧlu K, Savaci S: The effects of sevoflurane, isoflurane and desflurane on QT interval of the ECG. Eur J Anaesthesiol 2004; 21:566-570
5. Schmeling WT, Warltier DC, McDonald DJ, Madsen KE, Atlee JL, Kampine JP: Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans. Anesth Analg 1991; 72:137-144
6. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R: The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000; 21:1216-1231 (Pubitemid 30487769)
7. Anderson ME, Al-Khatib SM, Roden DM, Califf RM: Duke Clinical Research Institute/American Heart Journal Expert Meeting on Repolarization Changes: Cardiac repolarization: Current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 2002; 144:769-781
8. Hedley PL, Jørgensen P, Schlamowitz S, Wangari R, Moolman- Smook J, Brink PA, Kanters JK, Corfield VA, Christiansen M: The genetic basis of long QT and short QT syndromes: A mutation update. Hum Mutat 2009; 30:1486-1511
9. Schwartz PJ, Priori SG, Napolitano C: How really rare are rare diseases?: The intriguing case of independent compound mutations in the long QT syndrome. J Cardiovasc Electrophysiol 2003; 14:1120-1121
10. Roden DM: Human genomics and its impact on arrhythmias. Trends Cardiovasc Med 2004; 14:112-116
11. Moss AJ, Kass RS: Long QT syndrome: From channels to cardiac arrhythmias. J Clin Invest 2005; 115:2018-2024
12. Zipes DP: The long QT interval syndrome. A Rosetta stone for sympathetic related ventricular tachyarrhythmias. Circulation 1991; 84:1414-1419
13. Singh BN, Wadhani N: Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs. J Cardiovasc Pharmacol Ther 2004; 9:S85-97
14. Yang T, Snyders D, Roden DM: Drug block of I(kr): Model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 2001; 38:737-744
15. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH: Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270:2590-2597
16. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL: Torsade de pointes: The long-short initiating sequence and other clinical features: Observations in 32 patients. J Am Coll Cardiol 1983; 2:806-817
17. Roden DM, Woosley RL, Primm RK: Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. Am Heart J 1986; 111:1088-1093
18. Choy AM, Darbar D, Dell'Orto S, Roden DM: Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol 1999; 34:396-401
19. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341:857-865
20. Houltz B, Darpö B, Edvardsson N, Blomström P, Brachmann J, Crijns HJ, Jensen SM, Svernhage E, Vallin H, Swedberg K: Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: A prospective study. Pacing Clin Electrophysiol 1998; 21:1044-1057
21. Piotrovsky V: Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J 2005; 7:E609-24
22. Locati EH, Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Lehmann MH, Towbin JA, Priori SG, Napolitano C, Robinson JL, Andrews M, Timothy K, Hall WJ: Age- and sexrelated differences in clinical manifestations in patients with congenital long-QT syndrome: Findings from the International LQTS Registry. Circulation 1998; 97:2237-2244
23. Pratt CM, Ruberg S, Morganroth J, McNutt B, Woodward J, Harris S, Ruskin J, Moye L: Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: Distinguishing a drug effect from spontaneous variability. Am Heart J 1996; 131:472-480
24. Khongphatthanayothin A, Lane J, Thomas D, Yen L, Chang D, Bubolz B: Effects of cisapride on QT interval in children. J Pediatr 1998; 133:51-56
25. Roden DM: Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350:1013-1022
26. Lin YL, Kung MF: Magnitude of QT prolongation associated with a higher risk of torsades de pointes. Pharmacoepidemiol Drug Saf 2009; 18:235-239
27. Chan A, Isbister GK, Kirkpatrick CM, Dufful SB: Druginduced QT prolongation and torsades de pointes: Evaluation of a QT nomogram. QJM 2007; 100:609-615
28. Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J: Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. ANESTHESIOLOGY 2005; 102:1094-1100
29. Woosley RL, Chen Y, Freiman JP, Gillis RA: Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532-1536
30. Lee WM: Drug-induced hepatotoxicity. N Engl J Med 2003; 349:474-485
31. Hennessy S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF, Glasser DB, Morrison MF, Strom BL: Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: Cohort study using administrative data. BMJ 2002; 325:1070
32. Nuttall GA, Eckerman KM, Jacob KA, Pawlaski EM, Wigersma SK, Marienau ME, Oliver WC, Narr BJ, Ackerman MJ: Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population? ANESTHESIOLOGY 2007; 107:531-536
33. Morita H, Wu J, Zipes DP: The QT syndromes: Long and short. Lancet 2008; 372:750-763